FDA Approvals Roundup: Besremi
A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).New approval
Besremi okayed for rare blood disease
PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft injection) has been approved for treating adults with polycythemia vera, a blood disease caused by a JAK2V617F mutation that results in overproduction of red blood cells (RBCs).
The monopegylated, long-acting interferon alfa-2b reduces excess RBCs and can maintain normal RBC levels for at least a year. The disease is also treated through phlebotomy, a procedure that removes excess RBCs though a cannula inserted into a vein.
Approval of the biologics license application for Besremi was based on efficacy findings from the multicenter, single-arm PEGINVERA trial in which 51 patients from the indicated population received the study drug for an average of 5 years. Overall, 61% of patients had a complete hematological response (CHR), defined as RBC volume, <45%, without a recent phlebotomy; normal white cell and platelet counts; normal spleen size; no blood clots. Among those achieving CHR, time to response was 7.8 months of treatment and median duration of response (DoR) was 14.3 months. In all, 80% of patients achieved a hematological response, based only on hematocrit, platelets, and leukocytes, with a median DoR of 20.8 months.
Besremi received orphan drug designation for this indication.
The drug was approved with a boxed warning for risk of serious disorders, including aggravation of neuropsychiatric, autoimmune, ischemic, and infectious disorders.
×
Welcome to the new RAPS Digital Experience
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.